Gene therapy in Parkinson's disease: rationale and current status - Wikidata - wikimedia - TriplyDB

Gene therapy in Parkinson's disease: rationale and current status

Gene therapy in Parkinson's disease: rationale and current status

http://www.wikidata.org/entity/Q22241423

about

Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's disease Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives Lipopolyplex for Therapeutic Gene Delivery and Its Application for the Treatment of Parkinson's Disease Evaluation of helper-dependent canine adenovirus vectors in a 3D human CNS model.New small molecules for the treatment of Parkinson's disease.Nicotine as a potential neuroprotective agent for Parkinson's disease.Identification of key pathways and transcription factors related to Parkinson disease in genome wide.Focus on α4β2* and α6β2* nAChRs for Parkinson's Disease Therapeutics.When ethics constrains clinical research: trial design of control arms in "greater than minimal risk" pediatric trials α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Molecular chaperones in Parkinson's disease--present and future Clinical applications involving CNS gene transfer.Gene-based therapies in Parkinson's disease.Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.Stem cell challenges in the treatment of neurodegenerative disease.Proteolytic degradation of amyloid β-protein.Viral vectors and delivery strategies for CNS gene therapy.Recent gene therapy advancements for neurological diseases.Function and characteristics of PINK1 in mitochondria.Preconditioning as a potential strategy for the prevention of Parkinson's disease.Promising therapeutic agents for the treatment of Parkinson's disease.Serotonin synthesis and metabolism-related molecules in a human prostate cancer cell line Anterograde axonal transport of AAV2-GDNF in rat basal ganglia Cytoprotection against Hypoxic and/or MPP⁺ Injury: Effect of δ-Opioid Receptor Activation on Caspase 3.Religious beliefs, knowledge about science and attitudes towards medical genetics.

P2860

Q24337079-24DA3499-A5DC-4284-AFBB-456B1E926BC8 Q26747508-4274BF8A-0060-4E75-BED4-0AD84E6D10A7 Q26752578-A7635906-8591-4D06-ADF5-EBFE32921991 Q30843000-F6538BF7-B102-468E-A8A1-E9509AC16FB8 Q33636631-02905D25-2AF6-4716-8C92-330459810669 Q34281003-72CD4C19-68D7-4D8B-B745-661FE89C84B0 Q34449994-8924BB1B-F8C4-4F34-848D-02B703DBB99F Q34793270-43D0CA4B-1E60-469D-8EC5-968C173B07C4 Q35226105-59FBEA5D-1CF5-46FE-A48A-A9E5DE8FB621 Q35264378-2797BB66-9BEE-4F9E-9D43-1FFA05085770 Q35614156-F9706FA9-0853-4EC4-B2FD-D57B7FF0D83D Q35688796-4EDC5825-D84C-47B9-8F0C-DEB87F942AEE Q35899850-C46F21D2-BAD2-41B1-997E-6F2BFCBC2D09 Q37506503-09F0B7D8-94F3-4D23-A98D-EA1A506FC7F0 Q37846235-E067737E-D197-428C-82D9-FF1B77FB71BD Q37954422-4E672A11-591C-4C41-A423-22D1B4021D35 Q38016899-9E2517DE-00A3-4B57-B0E3-BC37BDF02A67 Q38029645-7BEE5F20-CC8F-43AE-B46F-E1EC85BC7075 Q38085469-F9AAEE64-7770-44A2-B093-5F4AC91119CC Q38093581-BDDDE87A-8D52-4537-B07F-36E73262EE4B Q38201685-4360C1D1-D8C7-49F5-ABB7-6427543DADF6 Q38767711-73DFE24B-C1C9-4FE1-8D74-F9D7612BD647 Q39586113-1AD8AC72-27FF-4906-9687-E5431E35C5E5 Q39628466-A93A153E-CEDA-41A1-B90F-284D2A48671A Q40952165-DD52D36A-0462-4547-8C30-2396F234AC04 Q44457746-C4465418-1BFC-4C00-B6D1-9C630CF638A5

P2860

Gene therapy in Parkinson's disease: rationale and current status

http://www.wikidata.org/entity/Q22241423

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Gene therapy in Parkinson's disease: rationale and current status

@ast

Gene therapy in Parkinson's disease: rationale and current status

@en

Gene therapy in Parkinson's disease: rationale and current status

@en-gb

Gene therapy in Parkinson's disease: rationale and current status

@nl

type

label

Gene therapy in Parkinson's disease: rationale and current status

@ast

Gene therapy in Parkinson's disease: rationale and current status

@en

Gene therapy in Parkinson's disease: rationale and current status

@en-gb

Gene therapy in Parkinson's disease: rationale and current status

@nl

prefLabel

Gene therapy in Parkinson's disease: rationale and current status

@ast

Gene therapy in Parkinson's disease: rationale and current status

@en

Gene therapy in Parkinson's disease: rationale and current status

@en-gb

Gene therapy in Parkinson's disease: rationale and current status

@nl

P1433

Q22241423-6D89B221-7FDE-4F34-8231-0ED47437F04C

P1476

Q22241423-8D78CF6E-4FED-4C10-B0A3-46C2DB017B3D

P2093

Q22241423-7FA91902-DDEA-4F1A-BE69-BB4E03F461F3

P2860

Q22241423-01271DAA-C511-494C-A704-F97B993B36D7

Q22241423-0529DD47-64AD-4350-B92A-F2622B915495

Q22241423-07CA65A9-7A9F-412D-B96B-40887297A050

Q22241423-091D234C-8E23-4A0C-87C3-A146A3275F38

Q22241423-0A7169E0-C101-47C8-8BED-15A7C89F88AE

Q22241423-102085D9-0A01-42EB-934C-A16C5844D6F9

Q22241423-107D3A01-B985-4CB1-BD12-9406F32CCCCE

Q22241423-12F65939-D8C0-4B6D-AC18-A54300CEBAB0

Q22241423-13011E59-779C-4AF5-9D07-7FED5FE04130

Q22241423-1568F11E-02B9-473C-AAA4-9238FA57F6DA

P2888

Q22241423-AF69B41B-9683-45D0-9EB3-DD47A47CB6D0

P304

Q22241423-4036DF8A-ED41-4133-BD10-DC984DDC8F38

P31

Q22241423-53795C2E-787C-409A-B61F-02A9ABBA014D

P3181

Q22241423-8A696A20-49A7-4FBD-BE07-4DD4326E4369

P356

Q22241423-A6CA74FE-973D-4AE9-8149-B9F8E946A663

P407

Q22241423-A0AB48F3-564E-46A7-9A05-A58F5F96FCDB

P433

Q22241423-6BE4D40E-D70F-4E00-A6C0-461F0F00C4DA

P478

Q22241423-A6034F26-F958-4ADA-9008-B7D4F8B8F61F

P50

Q22241423-6F49CB46-E34B-466B-9B85-17B72A03ADFA

P577

Q22241423-627049D9-C3F6-429B-A4E6-B194662DBF7D

P5875

Q22241423-B5360DAD-8B5F-4B8A-AEF6-8B6E8DC7566C

P6179

Q22241423-D6991431-BE02-43BB-B6E8-E3DF6835B64C

P698

Q22241423-2502AC97-AF17-4CBB-BF28-F516883BC145

P921

Q22241423-04114019-6CB5-4B7E-90A8-1A05854D2B55

Q22241423-39410E7F-C4B9-4DDB-AF53-1AAACDCFA473

P932

Q22241423-F30D4BD6-4C2B-4DB3-85A5-8ABE4F2CC5AA

P3181

P356

11533740-000000000-00000

P1433

P1476

Gene therapy in Parkinson's disease: rationale and current status

@en

P2093

Kathleen A Maguire-Zeiss

http://www.w3.org/2001/XMLSchema#string

P2860

Neurturin, a relative of glial-cell-line-derived neurotrophic factor

Genome-wide association study reveals genetic risk underlying Parkinson's disease

alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

alpha-Synuclein locus triplication causes Parkinson's disease

Alpha-synuclein in Lewy bodies

Genetics of Parkinson's disease

Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat

Occupation and risk of parkinsonism: a multicenter case-control study

P2888

11533740-000000000-00000

P304

177-192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

959424

http://www.w3.org/2001/XMLSchema#string

P356

10.2165/11533740-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41434440

http://www.w3.org/2001/XMLSchema#string

P6179

1026351862

http://www.w3.org/2001/XMLSchema#string

P698

20155994

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

2886503

http://www.w3.org/2001/XMLSchema#string